COVID-19, antibiotics and One Health: a UK environmental risk assessment
27 August 2020
There is growing interest in the role of secondary bacterial and fungal infections as a cause of increased morbidity and mortality in COVID-19 patients, with reports of up to 95% of COVID-19 inpatients being prescribed antibiotics. Concerns have been raised over the environmental implications of such a large-scale drug administration and statements made about the potential impacts of COVID-19-related antibiotic prescription on antimicrobial resistance (AMR) and other toxicological effects on the environment.
Further reading: Journal of Antimicrobial Chemotherapy
Author(s): Sean D W Comber, Mathew Upton, Shaun Lewin, Neil Powell, Thomas H Hutchinson
Clean Environment
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
